CMOSS-2 Research Kickoff Meeting

Occlusion of the middle cerebral artery is an important cause of ischaemic stroke and is currently treated with both drugs and bypass surgery. Previous studies have shown that the annual recurrence rate of stroke is as high as 10 percent with optimal pharmacological treatment and 7.3 times higher in patients with combined hemodynamic disorders. However, previous clinical trials have failed to demonstrate that bypass surgery is superior to optimal pharmacological treatment.

The Centre for Cerebral Blood Flow Reconstruction at Xuanwu Hospital, Capital Medical University, led the first multicentre randomised controlled trial in China to address this issue, the CMOSS trial, which suggests that optimal assessment and perioperative management may improve the safety and outcome of bypass grafting. The CMOSS study also showed that patients with chronic occlusion of symptomatic middle cerebral arteries and severe hemodynamic deficits in the corresponding blood-supplying regions had the poorest pharmacological outcomes and that they were precisely the population most likely to benefit from intracranial and extracranial vascular bypass surgery.

Therefore, based on the CMOSS study, led by Xuanwu Hospital of Capital Medical University, with Prof. Jiao Liqun from Xuanwu Hospital of Capital Medical University as the study sponsor and Prof. Gu Yuxiang from Huashan Hospital of Fudan University as the co-PI, 12 centres in the United Nations have initiated the CMOSS-2 study, which will verify whether surgery combined with medication is better than single-pharmacological treatment in the special high-risk group and is superior to monotherapy.

Professor Jiao Liqun from Xuanwu Hospital of Capital Medical University, together with PIs from 11 other centres, launched the CMOSS-2 study at the CFCVD Congress.

Prof.Yan Ma   | Xuanwu Hospital Capital Medical University

Prof.Liqun Jiao   | Xuanwu Hospital Capital Medical University

Prof.Yuxiang Gu   | Xuanwu Hospital Capital Medical University

Lastly, as Prof. Ma Yan said during her welcome address, "A single individual can cover a lot of ground, but a collective can cover more ground." The successful completion of the CMOSS-2 study relies on the collaborative efforts of the 12 participating units nationwide. Let us extend our best wishes for its successful conclusion./span>